Stage 4S neuroblastoma, a disseminated tumor with excellent outcome.

Abstract

OBJECTIVE:

To review the clinical features and outcome of all cases of stage 4S neuroblastoma treated at our center.

METHODS:

We retrospectively reviewed the files of all patients (n=75) with neuroblastoma treated at King Abdul-Aziz Medical City, Jeddah, Kingdom of Saudi Arabia between 1986 and 2005. We studied the clinical features and outcome of patients with stage 4S neuroblastoma.

RESULTS:

Six patients (8%) were confirmed to have stage 4S neuroblastoma. Three were boys with a median age at diagnosis of 4.5 months (range 28 days-11 months). Four patients required no intervention. The remaining 2 patients were treated with chemotherapy due to progressive hepatomegaly and respiratory distress. No patient required radiotherapy or surgical intervention. With a median follow up of 4 years (range 9 months-15.5 years), all patients are alive and well. Two patients continue to have a residual abdominal mass, while complete resolution occurred in the others.

CONCLUSION:

Stage 4S neuroblastoma is a special tumor that carries excellent prognosis. Spontaneous regression may occur and intervention is only required in symptomatic patients.

• Authors: Najla A Elimam, Ayad A Atra, Najwa Y Fayea, Tareq G Al-Asaad, Taha M Khattab, Ganadeel A Al-Sulami, Sami K Felimban
• Journal: Saudi medical journal (Saudi Med J) Vol. 27 Issue 11 Pg. 1734-6 (Nov 2006) ISSN: 0379-5284 [Print] Saudi Arabia
• PMID: 17106552 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Antineoplastic Agents
• Antineoplastic Agents, Alkylating
• Antineoplastic Agents, Phytogenic
• Vincristine
• Etoposide
• Doxorubicin
• Cyclophosphamide
• Carboplatin

Topics

• Adrenal Gland Neoplasms (diagnosis, diagnostic imaging, drug therapy, pathology)
• Adrenal Glands (pathology)
• Age Factors
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Antineoplastic Agents, Alkylating (administration & dosage, therapeutic use)
• Antineoplastic Agents, Phytogenic (administration & dosage, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Biopsy
• Carboplatin (administration & dosage, therapeutic use)
• Cyclophosphamide (administration & dosage, therapeutic use)
• Doxorubicin (therapeutic use)
• Etoposide (administration & dosage, therapeutic use)
• Female
• Follow-Up Studies
• Hepatomegaly (diagnosis, etiology)
• Humans
• Infant
• Infant, Newborn
• Liver Neoplasms (diagnosis, diagnostic imaging, drug therapy, pathology)
• Male
• Neoplasm Regression, Spontaneous
• Neoplasm Staging
• Neuroblastoma (diagnosis, diagnostic imaging, drug therapy, mortality, pathology, secondary)
• Prognosis
• Retrospective Studies
• Saudi Arabia
• Skin (pathology)
• Skin Neoplasms (diagnosis, pathology, secondary)
• Survival Analysis
• Time Factors
• Tomography, X-Ray Computed
• Treatment Outcome
• Vincristine (administration & dosage, therapeutic use)